Table 2

Adverse events in ≥2 patients

SAD Stage

MD Stage

No. (%) Patients

Placebo

(n = 6)

All Active

(n = 24)

Placebo

(n = 7)

1.5 mg/kg (SC) (n = 12)

3.5 mg/kg (SC) (n = 12)

5.0 mg/kg (IV)(n = 5)

All Active(n = 29)


Adverse Events

Any event

1 (17)

6 (25)

0 (0)

1 (8)

3 (25)

1 (20)

5 (17)

Nausea

0 (0)

2 (8)

0 (0)

0 (0)

1 (8)

0 (0)

1 (3)

Flank pain

0 (0)

2 (8)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

Fatigue

0 (0)

0 (0)

0 (0)

1 (8)

1 (8)

0 (0)

2 (7)

Pruritis

0 (0)

0 (0)

0 (0)

0 (0)

1 (8)

1 (20)

2 (7)

Rash

0 (0)

0 (0)

0 (0)

0 (0)

1 (8)

1 (20)

2 (7)

Serious Adverse Events

Any event

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)


IV, intravenous; MD, multiple dose; SAD, single ascending dose; SC, subcutaneous.

*Adverse events determined by investigators to be related to MTRX1011A by preferred term in ≥ 2 patients.

Scheerens et al. Arthritis Research & Therapy 2011 13:R177   doi:10.1186/ar3502

Open Data